← All trials
NCT03128905
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2017
- Primary completion
- Sep 1, 2018
- Completion date
- Feb 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Lille Catholic UniversityLead sponsor
- Lille Catholic UniversityOverall official - principal investigator
- Lille Catholic UniversityStudy chair
- University of Caen-NormandieCollaborator
- University of Picardie Jules VerneCollaborator
- Valenciennes Hospital CentreCollaborator
- University of ParisCollaborator
- University of LilleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.